Ultragenyx (RARE) awards RSUs and stock options to executive Pinion
Rhea-AI Filing Summary
Ultragenyx Pharmaceutical Inc. executive John Richard Pinion received new equity awards in the form of restricted stock units and stock options. He was granted 23,116 shares of common stock as RSUs under the company’s 2023 Incentive Plan, bringing his direct common stock holdings to 133,142 shares after the award. These RSUs vest in four equal annual installments on each anniversary of the grant date.
He also received a stock option covering 79,936 shares of common stock at an exercise price of $24.52 per share, expiring on April 16, 2036. One quarter of the option vests on the first anniversary of the grant date, with the remainder vesting in equal monthly installments over the following three years.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 79,936 | $0.00 | $0.00 |
| Grant/Award | Common Stock | 23,116 | $0.00 | $0.00 |
Footnotes (3)
- F1. Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
- F2. Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
- F3. On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Key Figures
Key Terms
Restricted Stock Units ("RSUs") financial
2023 Incentive Plan financial
Stock Option (Right to Buy) financial
vesting conditions financial
grant date financial
AI-generated analysis. How Rhea-AI works. Not financial advice.